• রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন
Indications:
SITAZID M 50/1000 is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Sitagliptin and Metformin is appropriate.
Pharmacology:
Sitagliptin: A DPP-4 inhibitor that increases the levels of incretin hormones, enhancing insulin secretion and decreasing glucagon levels in a glucose-dependent manner.
Metformin: A biguanide that decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Dosage:
Adults: One tablet (Sitagliptin 50mg + Metformin 1000mg) taken orally twice daily with meals. Dosage should be individualized based on the patient's current regimen, effectiveness, and tolerability.
Administration:
Take SITAZID M 50/1000 with meals to reduce gastrointestinal side effects. Swallow the tablet whole; do not crush or chew.
Interaction:
Alcohol: Increases the risk of lactic acidosis.
Cationic drugs (e.g., amiloride, digoxin): May compete for common renal tubular transport systems, increasing metformin levels.
Insulin or insulin secretagogues: May increase the risk of hypoglycemia when used concomitantly.
Contraindications:
Renal impairment (e.g., serum creatinine ≥1.5 mg/dL in males or ≥1.4 mg/dL in females)
Acute or chronic metabolic acidosis, including diabetic ketoacidosis
Hypersensitivity to Sitagliptin, Metformin, or any component of the formulation
Side Effects:
Common side effects include:
Diarrhea
Nausea
Vomiting
Headache
Upper respiratory tract infection
Hypoglycemia (especially when combined with insulin or sulfonylureas)
Pregnancy & Lactation:
Pregnancy: Use only if clearly needed and if the potential benefit justifies the potential risk to the fetus.
Lactation: It is unknown whether Sitagliptin or Metformin is excreted in human milk. Caution should be exercised when administered to a nursing woman.
Precautions & Warnings:
Monitor renal function before initiating therapy and periodically thereafter.
Use with caution in patients with hepatic impairment.
Discontinue in cases of dehydration, severe infection, or hypoxemia.
Temporarily discontinue before any radiologic studies involving intravascular administration of iodinated contrast materials.
Therapeutic Class:
Combination oral hypoglycemic preparations
Storage Conditions:
Store at a temperature below 30°C. Protect from light and moisture. Keep out of reach of children.